Risankizumab displayed linear pharmacokinetics across the doses evaluated in the phase I–III clinical trials in psoriasis, and a two-compartment model with first-order absorption and elimination best described its pharmacokinetics.

Body weight, anti-drug antibody, and baseline levels of albumin, high-sensitivity C-reactive protein, and serum creatinine were identified to be statistically correlated with risankizumab clearance; however, none of these covariates had a clinically meaningful impact on risankizumab exposures with the proposed psoriasis clinical regimen.

Risankizumab pharmacokinetics were similar between healthy subjects and patients with plaque psoriasis.